Last reviewed · How we verify
MV-012-968
At a glance
| Generic name | MV-012-968 |
|---|---|
| Sponsor | Meissa Vaccines, Inc. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine (PHASE2)
- Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months (PHASE1)
- Study of the Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seropositive Children (PHASE1)
- Safety and Immune Response to an Investigational Vaccine Against Respiratory Syncytial Virus in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MV-012-968 CI brief — competitive landscape report
- MV-012-968 updates RSS · CI watch RSS
- Meissa Vaccines, Inc. portfolio CI